Transarterial chemoembolization alone and in combination with other therapies: a comparative study in an animal HCC model

被引:34
作者
Maataoui, A [1 ]
Qian, J
Vossoughi, D
Khan, MF
Oppermann, E
Bechstein, WO
Vogl, TJ
机构
[1] Goethe Univ Frankfurt, Int Diagnost & Intervent Radiol, D-6000 Frankfurt, Germany
[2] Goethe Univ Frankfurt, Dept Visceral Surg, D-6000 Frankfurt, Germany
关键词
liver; hepatocellular carcinoma; transarterial chemoembolization;
D O I
10.1007/s00330-004-2517-8
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The purpose of this study is to compare transarterial chemoembolization (TACE) alone and in combination with other therapies in an animal model. Subcapsular implantation of a solid Morris hepatoma 3924A in the liver was carried out in 50 male ACI rats (day 0). Tumor volume (VI) was measured by MRI (day 13). After laparotomy and retrograde placement of a catheter into the gastroduodenal artery (day 14), the following protocols of the interventional procedure were applied: TACE (mitomycin C + liplodol) + immunotherapy (group A: TNFalpha, + IL-2, group B: OK-432 + IL-2); TACE + antianglogenesis therapy (group C: TNP-470, group D: endostatin); TACE alone in group E (control group). Tumor volume (V2) was assessed by MRI and the mean ratio of x (V2/V1) was calculated. Data were analyzed using Dunnett's t test (comparing therapeutic groups with the control group) and the Student-Newman-Keuls test (comparing significant therapeutic groups). Multivariate analysis showed a significant reduction in the tumor growth rate (P<0.05) in groups B (x=6.53) and C (x=4.01) compared to the mean ratio of the control group E (x=9.14). Significant results were observed in group C (P<0.05) in comparison with the other therapeutic groups. TACE combined with immunotherapy (OK-432) and antiangiogenesis therapy (TNP-470) retards tumor growth compared with TACE alone in an HCC animal model.
引用
收藏
页码:127 / 133
页数:7
相关论文
共 55 条
[1]   Chemoembolization for primary liver cancer [J].
Achenbach, T ;
Seifert, JK ;
Pitton, MB ;
Schunk, K ;
Junginger, T .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2002, 28 (01) :37-41
[2]   Review article: non-surgical treatment of hepatocellular carcinoma [J].
Alsowmely, AM ;
Hodgson, HJF .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (01) :1-15
[3]  
Bloomston M, 2002, AM SURGEON, V68, P827
[4]   Radiofrequency thermal ablation with expandable needle of focal liver malignancies: complication report [J].
Buscarini, E ;
Buscarini, L .
EUROPEAN RADIOLOGY, 2004, 14 (01) :31-37
[5]   ESTIMATION OF LIVER-TUMOR VOLUME USING DIFFERENT FORMULAS - AN EXPERIMENTAL-STUDY IN RATS [J].
CARLSSON, G ;
GULLBERG, B ;
HAFSTROM, L .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1983, 105 (01) :20-23
[6]   Surgery and ablative therapy for hepatocellular carcinoma [J].
Cha, C ;
DeMatteo, RP ;
Blumgart, LH .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2002, 35 (05) :S130-S137
[7]   THERAPEUTIC EFFECT OF TRANSCATHETER OILY CHEMOEMBOLIZATION THERAPY FOR ENCAPSULATED NODULAR HEPATOCELLULAR-CARCINOMA - CT AND PATHOLOGICAL FINDINGS [J].
CHOI, BI ;
KIM, HC ;
HAN, JK ;
PARK, JH ;
KIM, YI ;
KIM, ST ;
LEE, HS ;
KIM, CY ;
HAN, MC .
RADIOLOGY, 1992, 182 (03) :709-713
[8]   Radio-frequency tissue ablation of the liver: in vivo and ex vivo experiments with four different systems [J].
Denys, AL ;
De Baere, T ;
Kuoch, V ;
Dupas, B ;
Chevallier, P ;
Madoff, DC ;
Schnyder, P ;
Doenz, F .
EUROPEAN RADIOLOGY, 2003, 13 (10) :2346-2352
[9]  
Drixler TA, 2000, EUR J SURG, V166, P435
[10]  
Durand F, 2002, HEPATO-GASTROENTEROL, V49, P47